Erschienen in:
04.07.2019 | Cardiomyopathy
Cardiogenic shock in cancer
verfasst von:
Kalliopi Keramida, John T. Parissis, Ovidiu Chioncel, Dimitrios Farmakis
Erschienen in:
Heart Failure Reviews
|
Ausgabe 6/2019
Einloggen, um Zugang zu erhalten
Abstract
Cardiogenic shock (CS) is increasingly recognized in patients with malignancies, while cancer is independently associated with worse prognosis in CS. A number of conditions may lead to CS in cancer, including acute coronary syndromes, cardiomyopathy, takotsubo syndrome, myocarditis, pulmonary embolism, tamponade, and cardiac herniation. In these conditions, CS may be related to cancer itself or to cancer therapy, including surgery, chemotherapy, or radiotherapy. Given the significantly improved overall survival of patients with malignancies, the early recognition and proper management of CS in cancer become increasingly important. In the present paper, we review the available evidence on CS in patients with malignancies and highlight issues related to its management.